WARRINGTON, Pa., Nov. 10, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), a specialty biotechnology company dedicated to improving the standard of respiratory critical care through its KL4 surfactant and aerosol drug delivery technologies, will present at the Lazard Capital Markets 8th Annual Healthcare Conference. The conference will be held at The Pierre Hotel in New York City on November 15-16, 2011.
Discovery Labs is scheduled to present on Wednesday, November 16, 2011 at 2:00 PM EST. Management will provide an overview the Company and discuss near-term product opportunities for SURFAXIN® and AFECTAIR™.
About SURFAXIN®
SURFAXIN is an investigational drug for the prevention of RDS in premature infants. A New Drug Application for SURFAXIN is under review by the U.S. Food and Drug Administration, which has established March 6, 2012 as the target action date under the Prescription Drug User Fee Act (PDUFA) to complete its review and potentially grant US marketing approval. If approved, SURFAXIN would represent the first synthetic, peptide-containing surfactant for use in neonatal medicine and provide healthcare practitioners with a potential alternative to the currently approved, animal-derived surfactants that today are the standard of care to manage RDS in premature infants.
About AFECTAIR™
AFECTAIR is a series of proprietary ventilator circuit / patient interface connectors and related componentry. AFECTAIR simplifies the delivery of any inhaled therapies to critical care patients requiring ventilatory support. According to national health statistics and market assessment data, it is estimated that more than 1.3 million patients annually in the United States and European Union receive aerosolized medications while requiring ventilator support. Discovery Labs is implementing a regulatory plan that potentially will allow for the introduction of AFECTAIR in the United States and the European Union in 2012.
About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to create life-saving products for critical care patients with respiratory disease and improve the standard of care for pulmonary medicine. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized and aerosolized formulations. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient, targeted upper-respiratory or alveolar delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.discoverylabs.com.